Comparative Analysis of Fecal Microbiota in Healthy Controls and Pancreatic Cancer Patients: A Focus on Tumor Localization Differences in Pancreatic Head and Body–Tail

Annacandida Villani(Casa Sollievo della Sofferenza), Valerio Pazienza(Casa Sollievo della Sofferenza), Giovanna Cocomazzi(Casa Sollievo della Sofferenza), Edy Virgili(Università di Camerino), Gandino Mencarelli(Casa Sollievo della Sofferenza), Concetta Panebianco(Casa Sollievo della Sofferenza), Evaristo Maiello(La Maddalena), Viviana Contu(Ospedale Humanitas Gradenigo), Elena Binda(Casa Sollievo della Sofferenza), Francesco Perri(Casa Sollievo della Sofferenza), Tiziana Pia Latiano(Istituti di Ricovero e Cura a Carattere Scientifico)
Cancer Medicine
December 1, 2025
10.1002/cam4.71450
Cited by 0

Related Papers

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
|The Lancet Oncology|2020|322
The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype‐specific mechanisms†
|Hepatology|2007|226
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
|The Oncologist|2018|143
The Impact of the Female Genital Microbiota on the Outcome of Assisted Reproduction Treatments
|Microorganisms|2023|46
Hepatitis delta virus induces specific DNA methylation processes in Huh‐7 liver cancer cells
|FEBS Letters|2013|32